Description:FIELD OF THE INVENTION
The present invention relates to a phytopharmaceuticals formulation for treating influenza or corona virus disease. More specifically, the invention relates to formulation of a phytopharmaceuticals with which is organic in nature, non-toxic, food grade which anyone can have, anytime to cure influenza or corona virus disease.
BACKGROUND OF THE INVENTION
The world has faced unprecedented challenges due to the outbreak of the novel coronavirus (SARS-CoV-2), causing the corona virus pandemic. The global community is actively searching for effective remedies to combat and manage the disease. Vaccines have been developed, but they might not provide universal protection or could have limitations in certain populations. Therefore, there is a growing need for supplementary approaches to bolster the body's immune system and aid in the treatment of influenza/corona virus disease.
The corona virus disease pandemic has highlighted the importance of supporting the body's immune system to fight viral infections effectively. The current market is saturated with pharmaceutical drugs and supplements, but there is a demand for a natural, organic, and non-toxic food-grade solution that can be easily accessible to the general population.
Various medications, vaccines, and dietary supplements have been proposed as potential interventions for influenza/corona virus disease. However, some pharmaceuticals might have undesirable side effects, and vaccines may not be suitable for certain individuals due to medical conditions or age restrictions. Furthermore, synthetic supplements may raise concerns regarding long-term safety and sustainability.
WO2021229609A1 discloses a composition and method for prevention and treatment of viral infection caused by SARS-CoV-2 (COVID-19) in humans. In particular, the present invention relates to a composition comprising omega-3 liolacids Alpha-Linoleic Acid (ALA), Eicosapentaenoic Acid (EPA) or combinations thereof for the prevention and treatment of a symptom or condition associated with viral infection caused by SARS-CoV-2 (COVID-19) in humans. Alpha-Linoleic Acid (ALA) and Eicosapentaenoic Acid (EPA) are found to interfere with normal functions of SARS-CoV-2 proteins, Main protease, ADP ribose phosphatase and RNA dependent RNA polymerase, and inhibit the interactions of its spike protein with host ACE2 receptors, which are crucial for the establishment of infection. These omega-3 fatty acids also induce the host-directed response and acts as anti-inflammatory agents.
WO2022112806A2 discloses an invention for use in the control of COVID- 19 coronavirus infection, which became worldwide in 2020. The present invention relates to the methylation of a metabolite, macromolecule, protein, RNA, DNA involved in a multicomponent phytopharmaceuticals with easily mobilizable methyl groups for the control of viral infection, preferably SARS-COV-2 and IBV coronaviruses, a pharmaceutical or pharmaceutical composition comprising at least one methyl donor and at least one methyl acceptor in such a way that that the ratio of methyl donors to methyl acceptors is in accordance with the preferred molar ratios.
The need for the present invention arises as none of the existing inventions consists of an oral phytopharmaceuticals formulation that provides essential nutrients and organic compounds specifically selected to support the body's immune response against Corona virus disease-19. The formulation is derived from organic sources and is inherently non-toxic, ensuring that it is safe for consumption by people of all ages, including those with dietary restrictions.

OBJECTIVE OF THE INVENTION
The main objective of the present invention is to provide an oral phytopharmaceuticals formation sourced from organic, non-toxic solution to treat influenza or corona virus disease.
Yet another objective of the present invention is to ensure that the supplement is free from harmful chemicals and synthetic additives commonly found in traditional supplements.
Yet another objective of the present invention is to exclude harmful substances to ensure that it poses no threat of toxicity or adverse reactions to the consumer.
Yet another objective of the invention is to formulate a phytopharmaceuticals with ingredients that are recognized as safe for human consumption and are commonly found in various food products. This enhances the supplement's acceptance and accessibility.
Yet another objective of the invention is to make a formulation that includes specific compounds known for their potential in supporting the immune system and reducing the severity of influenza or corona virus disease.
Yet another objective of the formulation is to invent a formulation which can be easily produced, making it readily available for distribution and use on a global scale.
Further objectives, advantages, and features of the present invention will become apparent from the detailed description provided herein below, in which various embodiments of the disclosed invention are illustrated by way of example.

SUMMARY OF THE INVENTION
The present invention describes a formulation of an oral phytopharmaceuticals consisting of organic and non-toxic compounds. The formulation includes an organic aloe vera gel having concentration range of 10% to 20%, an organic green tea extract having concentration range of 5% to 10%, an organic lemon grass extract having concentration range of 5% to 10%, a natural protein blend having concentration range of 0.5% to 2%, water having concentration range of 70% to 80%, and at least two preservatives having concentration range of 0.1% to 0.2%.
In the embodiment, the method is for preparing the formulation for oral delivery of phytopharmaceuticals for treating influenza or corona virus disease. The method includes- water is put in a jacketed container and boiled to 80 degrees, the organic aloe vera gel, the organic green tea extract and the lemon grass extract are added to the jacketed container and the mixture in the jacketed container is left for 56 hours. The natural protein blend is added to the container and the container is kept for another 48 hours and the two preservatives are added to the mixture and are packed in the form of oral liquid supplements.

The main advantage of the present invention is that the present invention provides an oral phytopharmaceuticals formation sourced from organic, non-toxic solution to treat influenza or corona virus disease.
Yet another advantage of the present invention is that it ensures that the supplement is free from harmful chemicals and synthetic additives commonly found in traditional supplements.
Yet another advantage of the present invention is that it excludes harmful substances to ensure that it poses no threat of toxicity or adverse reactions to the consumer.
Yet another advantage of the invention is that it formulates a phytopharmaceuticals with ingredients that are recognized as safe for human consumption and are commonly found in various food products. This enhances the supplement's acceptance and accessibility.
Yet another advantage of the invention is that the formulation includes specific compounds known for their potential in supporting the immune system and reducing the severity of influenza or corona virus disease.
Yet another advantage of the formulation is that it invents a formulation which can be easily produced, making it readily available for distribution and use on a global scale.
Further objectives, advantages, and features of the present invention will become apparent from the detailed description provided herein below, in which various embodiments of the disclosed invention are illustrated by way of example.
BRIEF DESCRIPTION OF THE DRAWINGS
The accompanying drawings are incorporated in and constitute a part of this specification to provide a better understanding of the invention. The drawings illustrate one embodiment of the invention and together with the description, serve to explain the principles of the invention.
Fig.1 illustrates the Cytotoxicity assay using chromatin condensation.
Fig.2 illustrates the Pseudovirion Assay.
DETAILED DESCRIPTION OF THE INVENTION
Definition
The term “a” or “an”, as used herein, is defined as one. The term “plurality”, as used herein, is defined as two as or more than one. The term “another”, as used herein, is defined as at least a second or more. The terms “including” and/or “having”, as used herein, are defined as comprising (i.e., open language).
The term “comprising” is not intended to limit the present invention with such terminology rather is used in a wider sense. Any invention using the term comprising could be separated into one or more claims using “consisting” or “consisting of”. The term “comprising” may be used interchangeably with the terms “having” or “containing”.
Reference in this document to “one embodiment”, “certain embodiments”, “an embodiment”, “another embodiment”, and “yet another embodiment” or similar terms, throughout the document means that a specific feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of such phrases in various places, this specification throughout are not necessarily all referring to the same embodiment. Furthermore, the specific features, structures, or characteristics are combined in any suitable manner in one or more embodiments without limitation.
The term “or” as used herein is to be interpreted as inclusive or meaning any one or more combinations. Therefore, “A, B or C” means any of the following: “A; B; C; A and B; A and C; B and C; A, B and C”. An exception to this definition will occur only when a combination of elements, functions, steps, or acts are in mutually exclusive, inherently.
The drawings featured in the figures are to illustrate certain convenient embodiments of the present invention and are not to be considered as a limitation to that. Term "means" preceding a present participle of an operation indicates a desired function for which there is one or more embodiments, i.e., one or more methods, devices, or apparatuses for achieving the desired function and that one skilled in the art could select from these or their equivalent in view of the disclosure herein and use of the term "means" is not intended to be limiting.
As used herein, the term "one or more" generally refers to, but is not limited to, singular as well as the plural form of the term.
The present invention relates to an oral phytopharmaceuticals formulation for treating influenza or corona virus disease. The present invention includes an organic aloe vera gel, an organic green tea extract, an organic lemon tea extract, a protein blend, water and two preservatives. The organic aloe vera gel contains concentration from 10% to 20%, the organic green tea extract includes concentration range of 5% to 10%, the organic lemon grass extract includes concentration range of 5% to 10%, the natural protein blend having concentration range of 0.5% to 2%. In an embodiment, the natural protein blend is selected from pea protein and soya protein. Water includes concentration range of 70% to 80% and the two preservatives having concentration range of 0.1% to 0.2%. In an embodiment, the two preservatives include sodium benzoate and potassium sorbate. In an embodiment, the formulation is administered through oral dosage.

In the embodiment, the method is for preparing the formulation for oral delivery of phytopharmaceuticals for treating influenza or corona virus disease. The method includes: the water is put in a jacketed container and boiled to 80 degrees;
the organic aloe vera gel, the organic green tea extract and the lemon grass extract are added to the jacketed container;
the mixture in the jacketed container is left for 56 hours;
the natural protein blend is added to the container;
the container is kept for another 48 hours; and
the at least two preservatives are added to the mixture and are packed in the form of oral liquid supplements.

FIRST EXPERIMENT DATA

Fig. 1 shows Cytotoxicity assay using chromatin condensation, wherein the HEK293T cells stably expressing human ACE2 were grown on 96 glass bottom plates and allowed to grow for 24 hours. Then the cells were stained with fluorescent nuclear dye Hoechst 33342 at 5 ug per ml for five minutes. The cells were washed and replaced with fresh medium and maintained in CO2 incubator at 37 o C for 4 hours. The test samples were incubated with the cells at the indicated concentration. Fluorescent images were captured at 48h using DAPI filter set to visualize cell death using an inverted Fluorescent Microscope Nikon TiE. The images were captured with an EMCCD camera from Andor using NIS element software (Nikon). The cell death was interpreted based on the condensed chromatin compared to the control untreated wells (Fig. 1)
Based on the cytotoxicity, the sample at 1:1000 dilutions showed no cytotoxicity to the HEK293T cells.
Fig.2 shows Pseudovirion Assay, wherein the assay is based on the lentiviral backbone expressing Td tomato as a traceable marker. The utilized stable colon cancer cell HEK293T has been used for expressing human ACE2 as the SARS permissive cells. The procedure involves transfection of HEK Lenti Cells (Invitrogen)with the expression vector encoding Td tomato, a plasmid expressing Spike, and plasmids expressing the minimal set of lentiviral proteins necessary to assemble viral particles(Gag/Pol,Rev). The cells were transfected with the expression vectors prepared via Quiagen Midi prep using lipofectamine 2000 as per the manufacturer’s instruction. After 6h, the cells were replaced with fresh medium containing serum. From the transfected cells, SARSCoV2- Spike-pseudotypedlentiviral particles were collected at 72 hours and filtered using 0.45 micron filter and used to infect the HEK293T– hACE2 cells using polybrene as per the standard protocol. The test samples were incubated with pseudovirions containing medium at indicated dilutions. The media diluted pseudovirion sample acts as the control. After 48h the cells were imaged under florescent microscope and cells expressing Td tomato fluorescence were counted and percentage positivity was calculated based on the total number of cells in the field
Further objectives, advantages, and features of the present invention will become apparent from the detailed description provided herein, in which various embodiments of the disclosed present invention are illustrated by way of example and appropriate reference to accompanying drawings. Those skilled in the art to which the present invention pertains may make modifications resulting in other embodiments employing principles of the present invention without departing from its spirit or characteristics, particularly upon considering the foregoing teachings. Accordingly, the described embodiments are to be considered in all respects only as illustrative, and not restrictive, and the scope of the present invention is, therefore, indicated by the appended claims rather than by the foregoing description or drawings. Consequently, while the present invention has been described with reference to particular embodiments, modifications of structure, sequence, materials and the like apparent to those skilled in the art still fall within the scope of the invention as claimed by the applicant.
, Claims:I/ WE CLAIM
1. An oral phytopharmaceuticals formulation for treating influenza or corona virus disease, the formulation comprising of:
an at least organic aloe vera gel having concentration range of 10% to 20%;
an at least organic green tea extract having concentration range of 5% to 10%;
an at least organic lemon grass extract having concentration range of 5% to 10%;
an at least one natural protein blend having concentration range of 0.5% to 2%;
water having concentration range of 70% to 80%; and
an at least two preservatives having concentration range of 0.1% to 0.2%;

wherein, at certain percentage and temperature when blended with some vegan protein blend, it produces great anti virulent properties and inhibits Sars Corona virus disease to 50%.
2. The oral formulation as claimed in claim 1, wherein, the at least one natural protein blend is selected from pea protein and soya protein.

3. The oral formulation as claimed in claim 1, wherein, the at least two preservatives are sodium benzoate and potassium sorbate.

4. The oral formulation as claimed in claim 1, wherein, the formulation is administered through oral dosage.

5. A method for preparing the formulation as claimed in claim 1, the method comprising:
the water is put in a jacketed container and boiled to 80 degrees;
the organic aloe vera gel, the organic green tea extract and the lemon grass extract are added to the jacketed container;
the mixture in the jacketed container is left for 56 hours;
the natural protein blend is added to the container;
the container is kept for another 48 hours; and
the at least two preservatives are added to the mixture and are packed in the form of oral liquid supplements.